메뉴 건너뛰기




Volumn 17, Issue 1, 2015, Pages

Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: An open-label, pilot clinical trial

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; NILOTINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRIACYLGLYCEROL LIPASE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TRANSCRIPTOME;

EID: 84939440702     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0721-3     Document Type: Article
Times cited : (68)

References (42)
  • 1
    • 33847348491 scopus 로고    scopus 로고
    • Systemic sclerosis: a prototypic multisystem fibrotic disorder
    • Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557-67.
    • (2007) J Clin Invest , vol.117 , pp. 557-567
    • Varga, J.1    Abraham, D.2
  • 2
    • 0038076254 scopus 로고    scopus 로고
    • National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study
    • Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol. 2003;30:958.
    • (2003) J Rheumatol , vol.30 , pp. 958
    • Thomas, E.1    Symmons, D.P.2    Brewster, D.H.3    Black, R.J.4    Macfarlane, G.J.5
  • 3
    • 77956631231 scopus 로고    scopus 로고
    • Evidence-based management of rapidly progressing systemic sclerosis
    • Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol. 2010;24:387-400.
    • (2010) Best Pract Res Clin Rheumatol , vol.24 , pp. 387-400
    • Khanna, D.1    Denton, C.P.2
  • 4
    • 2142646426 scopus 로고    scopus 로고
    • TGF-beta signaling and the fibrotic response
    • Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J. 2004;18:816-27.
    • (2004) FASEB J , vol.18 , pp. 816-827
    • Leask, A.1    Abraham, D.J.2
  • 5
    • 65849108890 scopus 로고    scopus 로고
    • Role of PDGF in fibrotic diseases and systemic sclerosis
    • Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford). 2008;47:v2-4.
    • (2008) Rheumatology (Oxford) , vol.47 , pp. v2-v4
    • Trojanowska, M.1
  • 6
    • 36348968931 scopus 로고    scopus 로고
    • Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    • Kantarjian HM, Giles F, Gattermann N, Bhalia K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540-6.
    • (2007) Blood , vol.110 , pp. 3540-3546
    • Kantarjian, H.M.1    Giles, F.2    Gattermann, N.3    Bhalia, K.4    Alimena, G.5    Palandri, F.6
  • 7
    • 46749154199 scopus 로고    scopus 로고
    • Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis
    • Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jüngel A, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008;22:2214-22.
    • (2008) FASEB J , vol.22 , pp. 2214-2222
    • Akhmetshina, A.1    Dees, C.2    Pileckyte, M.3    Maurer, B.4    Axmann, R.5    Jüngel, A.6
  • 8
    • 84887463104 scopus 로고    scopus 로고
    • Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors
    • Maurer B, Distler A, Dees C, Khan K, Denton CP, Abraham D, et al. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Ann Rheum Dis. 2013;72:2039-46.
    • (2013) Ann Rheum Dis , vol.72 , pp. 2039-2046
    • Maurer, B.1    Distler, A.2    Dees, C.3    Khan, K.4    Denton, C.P.5    Abraham, D.6
  • 9
    • 84855283317 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors in the treatment of systemic sclerosis: The difficulty in interpreting proof-of-concept studies
    • Gordon J, Spiera R. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: The difficulty in interpreting proof-of-concept studies. Int J Rheumatol. 2011;2011:842181.
    • (2011) Int J Rheumatol , vol.2011 , pp. 842181
    • Gordon, J.1    Spiera, R.2
  • 10
    • 79955860261 scopus 로고    scopus 로고
    • Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial
    • Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70:1003-9.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1003-1009
    • Spiera, R.F.1    Gordon, J.K.2    Mersten, J.N.3    Magro, C.M.4    Mehta, M.5    Wildman, H.F.6
  • 11
    • 80155204477 scopus 로고    scopus 로고
    • A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease
    • Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011;63:3540-6.
    • (2011) Arthritis Rheum , vol.63 , pp. 3540-3546
    • Khanna, D.1    Saggar, R.2    Mayes, M.D.3    Abtin, F.4    Clements, P.J.5    Maranian, P.6
  • 12
    • 80155206225 scopus 로고    scopus 로고
    • Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center
    • Pope J, McBain D, Petrlich L, Watson S, Vanderhoek L, de Leon F, et al. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum. 2011;63:3547-51.
    • (2011) Arthritis Rheum , vol.63 , pp. 3547-3551
    • Pope, J.1    McBain, D.2    Petrlich, L.3    Watson, S.4    Vanderhoek, L.5    Leon, F.6
  • 13
    • 84868214290 scopus 로고    scopus 로고
    • Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial
    • Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol. 2012;167:1138-44.
    • (2012) Br J Dermatol , vol.167 , pp. 1138-1144
    • Prey, S.1    Ezzedine, K.2    Doussau, A.3    Grandoulier, A.S.4    Barcat, D.5    Chatelus, E.6
  • 14
    • 85028112070 scopus 로고    scopus 로고
    • Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
    • Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16:R144.
    • (2014) Arthritis Res Ther , vol.16 , pp. R144
    • Fraticelli, P.1    Gabrielli, B.2    Pomponio, G.3    Valentini, G.4    Bosello, S.5    Riboldi, P.6
  • 16
    • 0018887574 scopus 로고
    • Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis
    • (scleroderma)
    • Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
    • (1980) Arthritis Rheum , vol.23 , pp. 581-590
  • 17
    • 0034937852 scopus 로고    scopus 로고
    • Criteria for the classification of early systemic sclerosis
    • LeRoy EC, Medsger Jr TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-6.
    • (2001) J Rheumatol , vol.28 , pp. 1573-1576
    • LeRoy, E.C.1    Medsger, T.A.2
  • 18
    • 42649123535 scopus 로고    scopus 로고
    • National Cancer Institute
    • Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute. 2010. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf . Accessed 5 Aug 2015.
    • (2010)
  • 19
    • 85081879509 scopus 로고    scopus 로고
    • Highlights of Prescribing Information
    • Highlights of Prescribing Information. Novartis Pharmaceuticals. 2015. http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf . Accessed 5 Aug 2015.
    • (2015) Novartis Pharmaceuticals
  • 20
    • 84880326024 scopus 로고    scopus 로고
    • Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis
    • Hinchcliff M, Huang CC, Wood TA, Matthew Mahoney J, Martyanov V, Bhattacharyya S, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol. 2013;133:1979-89.
    • (2013) J Invest Dermatol , vol.133 , pp. 1979-1989
    • Hinchcliff, M.1    Huang, C.C.2    Wood, T.A.3    Matthew Mahoney, J.4    Martyanov, V.5    Bhattacharyya, S.6
  • 24
    • 9444225935 scopus 로고    scopus 로고
    • Java Treeview-extensible visualization of microarray data
    • Saldanha AJ. Java Treeview-extensible visualization of microarray data. Bioinformatics. 2004;20:3246-8.
    • (2004) Bioinformatics , vol.20 , pp. 3246-3248
    • Saldanha, A.J.1
  • 25
    • 27344435774 scopus 로고    scopus 로고
    • Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles
    • Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545-50. Epub 2005 Sep 30.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , pp. 15545-15550
    • Subramanian, A.1    Tamayo, P.2    Mootha, V.K.3    Mukherjee, S.4    Ebert, B.L.5    Gillette, M.A.6
  • 26
    • 0038054341 scopus 로고    scopus 로고
    • PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
    • Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267-73.
    • (2003) Nat Genet , vol.34 , pp. 267-273
    • Mootha, V.K.1    Lindgren, C.M.2    Eriksson, K.F.3    Subramanian, A.4    Sihag, S.5    Lehar, J.6
  • 27
    • 70449091786 scopus 로고    scopus 로고
    • Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
    • Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108-12.
    • (2009) Nature , vol.462 , pp. 108-112
    • Barbie, D.A.1    Tamayo, P.2    Boehm, J.S.3    Kim, S.Y.4    Moody, S.E.5    Dunn, I.F.6
  • 31
    • 79251546724 scopus 로고    scopus 로고
    • Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
    • Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141-5.
    • (2011) Blood , vol.117 , pp. 1141-1145
    • Kantarjian, H.M.1    Giles, F.J.2    Bhalla, K.N.3    Pinilla-Ibarz, J.4    Larson, R.A.5    Gattermann, N.6
  • 35
    • 33750367940 scopus 로고    scopus 로고
    • Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study
    • Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study. Ann Rheum Dis. 2006;65:1325-9.
    • (2006) Ann Rheum Dis , vol.65 , pp. 1325-1329
    • Khanna, D.1    Furst, D.E.2    Hays, R.D.3    Park, G.S.4    Wong, W.K.5    Seibold, J.R.6
  • 36
    • 0038799774 scopus 로고    scopus 로고
    • Natural History of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being
    • Medsger T. Natural History of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin N Am. 2003;255-273.
    • (2003) Rheum Dis Clin N Am. , pp. 255-273
    • Medsger, T.1
  • 37
    • 68049111578 scopus 로고    scopus 로고
    • Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials
    • Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum. 2009;60:2490-8.
    • (2009) Arthritis Rheum , vol.60 , pp. 2490-2498
    • Amjadi, S.1    Maranian, P.2    Furst, D.E.3    Clements, P.J.4    Wong, W.K.5    Postlethwaite, A.E.6
  • 39
    • 84863469731 scopus 로고    scopus 로고
    • Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis
    • Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, et al. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2012;64:3420-9.
    • (2012) Arthritis Rheum , vol.64 , pp. 3420-3429
    • Merkel, P.A.1    Silliman, N.P.2    Clements, P.J.3    Denton, C.P.4    Furst, D.E.5    Mayes, M.D.6
  • 40
    • 76649115304 scopus 로고    scopus 로고
    • A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity
    • Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, et al. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol. 2010;130:694-705.
    • (2010) J Invest Dermatol , vol.130 , pp. 694-705
    • Sargent, J.L.1    Milano, A.2    Bhattacharyya, S.3    Varga, J.4    Connolly, M.K.5    Chang, H.Y.6
  • 41
    • 84922224910 scopus 로고    scopus 로고
    • Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms
    • Mahoney JM, Taroni J, Martyanov V, Wood TA, Greene CS, Pioli PA, et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput Biol. 2015;11(1):e1004005.
    • (2015) PLoS Comput Biol , vol.11 , Issue.1
    • Mahoney, J.M.1    Taroni, J.2    Martyanov, V.3    Wood, T.A.4    Greene, C.S.5    Pioli, P.A.6
  • 42
    • 84935081357 scopus 로고    scopus 로고
    • Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts
    • Johnson ME, Mahoney JM, Taroni J, Sargent JL, Marmarelis E, Wu MR, et al. Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts. PLoS One. 2015;10(1):e0114017. doi: 10.1371/journal.pone.0114017 .
    • (2015) PLoS One , vol.10 , Issue.1
    • Johnson, M.E.1    Mahoney, J.M.2    Taroni, J.3    Sargent, J.L.4    Marmarelis, E.5    Wu, M.R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.